Glimepiride Stella

Glimepiride

Type 2 DM when diet, physical exercise & wt reduction alone are inadequate.

Initially 1 mg daily. Based on glycaemic control & in a stepwise manner w/ an interval of about 1-2 wk between each step, increase dose to 2, 3, or 4 mg daily if control is unsatisfactory. Max: 6 mg daily.

Should be taken with food: Take immediately before or during breakfast, or the 1st main meal of the day. Do not skip meals.

Hypersensitivity to glimepiride, other sulfonylureas or sulfonamides. Patients w/ insulin-dependent diabetes; diabetic coma; ketoacidosis; severe renal or hepatic impairment.

Treatment may lead to hypoglycaemia when meals are taken at irregular hr or skipped altogether. Regularly monitor glucose levels in blood & urine, w/ HbA1c proportion determination. Regularly monitor hepatic & haematological parameters (especially leucocytes & thrombocytes). Rare risk of severe reactions eg, Stevens-Johnson syndrome & toxic epidermal necrolysis. Patients w/ G6PD-deficiency; rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May impair ability to drive or operate machinery. Do not use during pregnancy. Do not breastfeed during treatment. Not recommended in paed population.

Rare: Thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, erythropenia, haemolytic anaemia, pancytopenia; hypoglycaemia.

Metabolism is influenced by concomitant administration of CYP2C9 inducers (eg, rifampicin) or inhibitors (eg, fluconazole). Potentiated blood-glucose-lowering effect w/ phenylbutazone, azapropazone & oxyfenbutazone; insulin & oral antidiabetic products eg, metformin; salicylates & p-amino-salicylic acid; anabolic steroids & male sex hormones; chloramphenicol, certain long-acting sulfonamides, tetracyclines, quinolone antibiotics & clarithromycin; coumarin anticoagulants; fenfluramine; disopyramide; fibrates; ACE inhibitors; fluoxetine, MAOIs; allopurinol, probenecid, sulfinpyrazone; sympatholytics; cyclophosphamide, trophosphamide & iphosphamides; miconazole, fluconazole; pentoxifylline (high-dose parenteral); tritoqualine. Weakened blood-glucose-lowering effect w/ oestrogens & progestogens; saluretics, thiazide diuretics; thyroid-stimulating agents, glucocorticoids; phenothiazine derivatives, chlorpromazine; adrenaline & sympathicomimetics; nicotinic acid (high dosages) & nicotinic acid derivatives; laxatives (long-term use); phenytoin, diazoxide; glucagon, barbiturates & rifampicin; acetazolamide. H₂ antagonists, β-blockers, clonidine & reserpine may lead to either potentiated or weakened blood-glucose-lowering effect. Reduced or absent signs of adrenergic counter-regulation to hypoglycaemia w/ sympatholytic medicinal products eg, β-blockers, clonidine, guanethidine & reserpine. Potentiated or weakened hypoglycaemic action w/ alcohol. Potentiated or weakened effects of coumarin derivatives. Reduced GIT absorption w/ colesevelam.

Antidiabetic Agents

A10BB12 - glimepiride ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.

P₁S₁S₃